Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 25;12(3):e057019.
doi: 10.1136/bmjopen-2021-057019.

What, how, when and who of trial results summaries for trial participants: stakeholder-informed guidance from the RECAP project

Affiliations

What, how, when and who of trial results summaries for trial participants: stakeholder-informed guidance from the RECAP project

Hanne Bruhn et al. BMJ Open. .

Erratum in

Abstract

Objective: To generate stakeholder informed evidence to support recommendations for trialists to implement the dissemination of results summaries to participants.

Design: A multiphase mixed-methods triangulation design involving Q-methodology, content analysis, focus groups and a coproduction workshop (the REporting Clinical trial results Appropriately to Participants project).

Setting: Phase III effectiveness trials.

Participants: A range of participants were included from ongoing and recently completed trials, public contributors, trialists, sponsors, research funders, regulators, ethics committee members.

Results: Fewer than half of the existing trial result summaries contained information on the clinical implications of the study results, an item deemed to be of high importance to participants in the Q-methodology study. Priority of inclusion of a thank you message varied depending on whether considering results for individuals or populations. The need for personally responsive modes of sharing trial result summaries was highlighted as important. Ideally, participants should be the first to know of the results with regard to the timing of sharing results summaries but given this can be challenging it is therefore important to manage expectations. In addition to patients, it was identified that it is important to engage with a range of stakeholders when developing trial results summaries.

Conclusions: Results summaries for trial participants should cover four core questions: (1) What question the trial set out to answer?; (2) What did the trial find?; (3) What effect have the trial results had and how will they change National Health Service/treatment?; and (4) How can I find out more? Trial teams should develop appropriately resourced plans and consult patient partners and trial participants on how 'best' to share key messages with regard to content, mode, and timing. The study findings provide trial teams with clear guidance on the core considerations of the 'what, how, when and who' with regard to sharing results summaries.

Keywords: Clinical trials; QUALITATIVE RESEARCH; STATISTICS & RESEARCH METHODS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Viewpoint 1 Q-sort: ‘population view’. PPI, patient and public involvement.
Figure 2
Figure 2
Viewpoint 2 Q-sort: ‘individual view’. PPI, patient and public involvement.
Figure 3
Figure 3
RECAP: plain language summary template. HRA, Health Research Authority; NHS, National Health Service; RECAP, REporting Clinical trial results Appropriately to Participants.

References

    1. WMA Declaration of Helsinki – ethical principles for medical research involving human subjects, 2018. Available: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-pr... [Accessed 26 Jul 2021].
    1. Make it public: transparency and openness in health and social care research, 2021. Available: https://www.hra.nhs.uk/planning-and-improving-research/policies-standard... [Accessed 26 Jul 2021].
    1. Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med 2008;5:e91. 10.1371/journal.pmed.0050091 - DOI - PMC - PubMed
    1. Raza MZ, Bruhn H, Gillies K. Dissemination of trial results to participants in phase III pragmatic clinical trials: an audit of trial Investigators intentions. BMJ Open 2020;10:e035730. 10.1136/bmjopen-2019-035730 - DOI - PMC - PubMed
    1. Schroter S, Price A, Malički M, et al. Frequency and format of clinical trial results dissemination to patients: a survey of authors of trials indexed in PubMed. BMJ Open 2019;9:e032701. 10.1136/bmjopen-2019-032701 - DOI - PMC - PubMed

Publication types